Advances of immune-checkpoint inhibition of CTLA-4 in pancreatic cancer

被引：6
作者：
Ni, Ran [1 ,2 ]
Hu, Zhiming [1 ,3 ]
Tao, Ran [2 ]
机构：
[1] Zhejiang Chinese Med Univ, Clin Med Coll 2, Hangzhou, Peoples R China
[2] Zhejiang Prov Peoples Hosp, Affiliated Peoples Hosp, Hangzhou Med Coll, Gen Surg Canc Ctr Dept Hepatobiliary & Pancreat Su, Hangzhou, Zhejiang, Peoples R China
[3] Tongde Hosp Zhejiang Prov, Dept Hepatobiliary & Pancreat Surg, Hangzhou 310012, Peoples R China
来源：
BIOMEDICINE & PHARMACOTHERAPY | 2024年 / 179卷
关键词：
Pancreatic cancer; Immune checkpoint inhibitor; CTLA-4; Combination therapy; Tumor microenvironment; T-CELL INFILTRATION; I DOSE-ESCALATION; CLINICAL-SIGNIFICANCE; PD-1; BLOCKADE; IMMUNOTHERAPY; ANTI-CTLA-4; IPILIMUMAB; SURVIVAL; THERAPY; COMBINATION;
D O I：
10.1016/j.biopha.2024.117430
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Targeting checkpoints for immune cell activation has been acknowledged known as one of the most effective way to activate anti-tumor immune responses. Among them, drugs targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) are approved for clinical treatment though several more are in advanced stages of development, which demonstrated durable response rates and manageable safety profile. However, its therapy efficacy is unsatisfactory in pancreatic cancer (PC), which can be limited by the overall condition of patients, the pathological type of PC, the expression level of tumor related genes, etc. To improve clinical efficiency, various researches have been conducted, and the efficacy of combination therapy showed significantly improvement compared to monotherapy. This review analyzed current strategies based on anti-CTLA-4 combination immunotherapy, providing totally new idea for future research.
引用
收藏
页数：15
相关论文
共 184 条
[1]   LAG-3 as the third checkpoint inhibitor [J].
Aggarwal, Vaishali ;
Workman, Creg J. ;
Vignali, Dario A. A. .
NATURE IMMUNOLOGY, 2023, 24 (9) :1415-1422
[2]   A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer [J].
Aglietta, M. ;
Barone, C. ;
Sawyer, M. B. ;
Moore, M. J. ;
Miller, W. H., Jr. ;
Bagala, C. ;
Colombi, F. ;
Cagnazzo, C. ;
Gioeni, L. ;
Wang, E. ;
Huang, B. ;
Fly, K. D. ;
Leone, F. .
ANNALS OF ONCOLOGY, 2014, 25 (09) :1750-1755
[3]   CAR-T cell combination therapy: the next revolution in cancer treatment [J].
Al-Haideri, Maysoon ;
Tondok, Santalia Banne ;
Safa, Salar Hozhabri ;
Maleki, Ali Heidarnejad ;
Rostami, Samaneh ;
Jalil, Abduladheem Turki ;
Al-Gazally, Moaed E. ;
Alsaikhan, Fahad ;
Rizaev, Jasur Alimdjanovich ;
Mohammad, Talar Ahmad Merza ;
Tahmasebi, Safa .
CANCER CELL INTERNATIONAL, 2022, 22 (01)
[4]   Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer [J].
Anagnostou, Valsamo ;
Smith, Kellie N. ;
Forde, Patrick M. ;
Niknafs, Noushin ;
Bhattacharya, Rohit ;
White, James ;
Zhang, Theresa ;
Adleff, Vilmos ;
Phallen, Jillian ;
Wali, Neha ;
Hruban, Carolyn ;
Guthrie, Violeta B. ;
Rodgers, Kristen ;
Naidoo, Jarushka ;
Kang, Hyunseok ;
Sharfman, William ;
Georgiades, Christos ;
Verde, Franco ;
Illei, Peter ;
Li, Qing Kay ;
Gabrielson, Edward ;
Brock, Malcolm V. ;
Zahnow, Cynthia A. ;
Baylin, Stephen B. ;
Scharpf, Robert B. ;
Brahmer, Julie R. ;
Karchin, Rachel ;
Pardoll, Drew M. ;
Velculescu, Victor E. .
CANCER DISCOVERY, 2017, 7 (03) :264-276
[5]   Advances in Pancreatic Ductal Adenocarcinoma Treatment [J].
Anderson, Eric M. ;
Thomassian, Shant ;
Gong, Jun ;
Hendifar, Andrew ;
Osipov, Arsen .
CANCERS, 2021, 13 (21)
[6]   Targeting Cbl-b in cancer immunotherapy [J].
Augustin, Ryan C. ;
Bao, Riyue ;
Luke, Jason J. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (02)
[7]   Conserved pan-cancer microenvironment subtypes predict response to immunotherapy [J].
Bagaev, Alexander ;
Kotlov, Nikita ;
Nomie, Krystle ;
Svekolkin, Viktor ;
Gafurov, Azamat ;
Isaeva, Olga ;
Osokin, Nikita ;
Kozlov, Ivan ;
Frenkel, Felix ;
Gancharova, Olga ;
Almog, Nava ;
Tsiper, Maria ;
Ataullakhanov, Ravshan ;
Fowler, Nathan .
CANCER CELL, 2021, 39 (06) :845-+
[8]   Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance [J].
Bagchi, Sreya ;
Yuan, Robert ;
Engleman, Edgar G. .
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 16, 2021, 2021, 16 :223-249
[9]  
Bajwa Ravneet, 2019, J Clin Med Res, V11, P225, DOI 10.14740/jocmr3750
[10]   A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells [J].
Barsoum, Ivraym B. ;
Smallwood, Chelsea A. ;
Siemens, D. Robert ;
Graham, Charles H. .
CANCER RESEARCH, 2014, 74 (03) :665-674
12345678910